[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Thomas Walter; Henning Jann; Catherine Ansquer; Emmanuel Deshayes; Rocio Garcia-Carbonero; Alexandre Teulé; Richard Baum; Hein Verberne; Jarosław Ćwikła; Rajaventhan Srirajaskanthan; Louis de Mestier; Chiara Grana; Andreas Buck; Dieter Hörsch; Marianne Pavel; Lawrence Dierickx; Michael Michael; Jonathan Strosberg; Attila Kollár; Paula Jimenez-Fonseca; Anja Rinke; Maribel del Olmo-García; Anthime Flaus; Jorge Hernando; Andreas Kluge; Monika Breuninger; Serhii Melnyk; Konstantin Zhernosekov; Jaume Capdevila

doi:10.1016/S0140-6736(26)00604-5

Retour

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Article de revue scientifique

Avec comité de lecture

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard Baum, Hein Verberne, Jarosław Ćwikła, Rajaventhan Srirajaskanthan, …

The Lancet

07/2026

DOI: https://doi.org/10.1016/S0140-6736(26)00604-5

PMID: 42392118

Résumé

Peptide receptor radionuclide and targeted therapy are both approved treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs), but clinical evidence for preferred sequencing is scarce. The COMPETE trial evaluated the efficacy and harms of peptide receptor radionuclide therapy ([177Lu]Lu-edotreotide) versus targeted molecular therapy (everolimus) in patients with advanced, progressive, somatostatin receptor-positive GEP NETs.

Fichiers et liens (1)

url

Find in HALAfficher

Indicateurs

1 Consultations de la notice

Détails

Titre: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Créateurs - sans rôle: Thomas Walter - Hôpital Edouard Herriot
Henning Jann - Charité - Universitätsmedizin Berlin
Catherine Ansquer - Centre Hospitalier Universitaire de Nantes
Emmanuel Deshayes - Université de Montpellier, IRCM - Institut de Recherche en Cancérologie de Montpellier
Rocio Garcia-Carbonero - Hospital Universitario 12 De Octubre
Alexandre Teulé - Institut Català d'Oncologia
Richard Baum - Helios Dr. Horst Schmidt Kliniken Wiesbaden
Hein Verberne - Amsterdam University Medical Centers
Jarosław Ćwikła - University of Warmia and Mazury in Olsztyn
Rajaventhan Srirajaskanthan - King's College Hospital
Louis de Mestier - Université Paris Cité
Chiara Grana - European Institute of Oncology
Andreas Buck - Universitätsklinikum Würzburg
Dieter Hörsch - Zentralklinik Bad Berka
Marianne Pavel - Comprehensive Cancer Center Erlangen
Lawrence Dierickx - Institut Claudius Regaud
Michael Michael - The University of Melbourne
Jonathan Strosberg - Moffitt Cancer Center
Attila Kollár - University Hospital of Bern
Paula Jimenez-Fonseca - Hospital Universitario Central de Asturias
Anja Rinke - Philipps University of Marburg
Maribel del Olmo-García - Hospital Universitari i Politècnic La Fe
Anthime Flaus - Hôpital Louis Pradel
Jorge Hernando - Vall d'Hebron Hospital Universitari
Andreas Kluge - ABX-CRO Advanced Pharmaceutical Services (Germany)
Monika Breuninger - Isotopen Technologien München (Germany)
Serhii Melnyk - Isotopen Technologien München (Germany)
Konstantin Zhernosekov - Isotopen Technologien München (Germany)
Jaume Capdevila - Vall d'Hebron Hospital Universitari
Détails de publication: The Lancet
Identifiants: 99260668009311
Unité académique: IRCM - Institut de Recherche en Cancérologie de Montpellier
Langue: Anglais
Type de ressource: Article de revue scientifique
Champs locaux: hal-05679934